 "Zydus receives tentative approval from USFDA for Tofacitinib tablets")
Drug firm Zydus Cadila Saturday said it has received tentative approval from the US health regulator to market Tofacitinib tablets, used for the treatment of rheumatoid arthritis.
Tofacitinib is used alone or with other medications to treat moderate to severe forms of rheumatoid arthritis, the company said in a BSE filing.
It helps to decrease pain, tenderness and swelling in the joints, it added.
It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has 260 approvals and has so far filed over 350 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04, it added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app